Effect of co-administered lopinavir/ritonavir and sulfamethoxazole/trimethoprim on kidney function and architecture of albino rats

Adikwu Elias, Deo Oputiri, Oru-Bo Precious Geoffrey, Zidafamor Jimmy, Obele Rejoice, Asalagha Marian, Akpe Ebibowei, Akpen Anthony, Demien Ayaowei

Abstract


Background: Human immunodeficiency virus/acquired immune deficiency syndrome is usually associated with co-infections which has allow the concurrent use of sulfamethoxazole/trimethoprim (SMX/TMP)+Lopinavir/ritonavir (LPV/r). The concurrent use of these drugs may have possible adverse effects on the kidney because they are individually associated with adverse renal events. This study, therefore evaluates the possible effect of co-administered SMX/TMP+LPV/r on kidney function and architecture of albino rats.

Methods: Seventy five (75) animals which were divided into five groups were used in this study. Group A, which served as control, contained 15 animals which were treated with 1% ethanol orally. Group B-E, which contained 15 animals each, was further subdivided into three groups of five animals each. Animals in these groups were treated with oral doses of SMX/TMP (11.2/2.3 mg/kg), LPV/r (11.4/2.9 mg/kg), and combined doses of SMX/TMP+LPV/r for 2-8 weeks respectively. Serum levels of creatinine, urea, and uric acid were evaluated. Kidney tissue was evaluated for malondialdehyde (MDA), superoxide dismutase (SOD), and histopathological changes.

Results: Treatment with single doses of SMX/TMP, and LPV/r, produced a time-dependent increase in serum creatinine and urea. But no significant synergistic effects on serum creatinine and urea were observed when these agents were co-administered. Treatment with single and combine doses of these agents had no significant effects on serum uric acid level. Treatment with single agents produced time-dependent increase in kidney MDA and decrease in SOD level but without any significant effects when these agents were co-administered. Kidney of animals treated with single doses of these agents showed hypercellarity of the interstitium of the glomeruli and vascular congestion with no synergistic effects when these agents were co-administered.

Conclusion: Concurrent use of SMX/TMP+LPV/r in the management of HIV and co-infection may not have any deleterious effect on the renal system.


Keywords


Kidney, Lopinavir/Ritonavir, Sulfamethoxazole/Trimethoprim, Toxicity, Rats

Full Text:

PDF

References


UNAIDS and WHO. AIDS Epidemic Update 2007. Joint United Nations Programme on HIV/AIDS and World Health Organization Geneva, Switzerland: World Health Organization; 2007.

WHO. Towards Universal Access: scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress Report. Geneva, Switzerland: World Health Organization; 2007.

WHO. World Health Statistics 2013. Geneva, Switzerland: World Health Organization; 2013.

Battegay M, Elzi L. Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities. Swiss Med Wkly 2009;139(39-40):564-70.

Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med. 2006;14(5):159-63.

Vilar FJ, Khoo SH, Walley T. The management of Pneumocystis carinii pneumonia. Br J Clin Pharmacol. 1999;47(6):605-9.

Allroggen A, Frese A, Rahmann A, Gaubitz M, Husstedt IW, Evers S. HIV associated arthritis: case report and review of the literature. Eur J Med Res. 2005 29;10:305-8.

Elias A, Ijeoma O, Edikpo NJ, Oputiri D, Oru-Bo PO. Tenofovir renal toxicity: evaluation of cohorts and clinical studies-part 2. Pharmacol Pharma. 2014;5:97-111.

Anzai N, Endou H. Renal drug transporters and nephrotoxicity. Proceedings of 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Aatex. Vol. 14, 2007. p. 447-52. Special Issue.

Kielhofner MA. Trimethoprim-sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Tex Heart Inst J. 1990;17(2):86-93.

Hull MW, Harris M, Lima V, Guillemi S, Harrigan PR, Montaner JS. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation. J Clin Pharmacol. 2009;49:155-61.

Reyskens KM, Fisher TL, Schisler JC, O’Connor WG, Rogers AB, Willis MS, et al. Cardio-metabolic effects of HIV protease inhibitors (lopinavir/ritonavir). PLoS One. 2013;8(9):e73347.

Nathiya S, Nandhini A. Evaluation of antioxidant effect of Salacia oblonga against aluminum chloride induced visceral toxicity in albino rats. Int J Basic Clin Pharmacol. 2014;3(2):315-31

Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421-31.

Beauchamp C, Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem. 1971;44(1):276-87.

Kind PR, King EJ. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol. 1954;7(4):322-6.

Annino JS, Giese RW. Clinical Chemistry. 4th edition. Boston: Little Brown; 1979: p. 170-7.

Toro G, Ackermann PG. Practical Clinical Chemistry. Boston: Little Brown; 1975: p. 148-56.

Drury RAB, Wallington EA, Cameron R. Carleton’s Histological Techniques. 4th edition. NY, USA: Oxford University Press; 1967: 279-80.

Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997;25(4):489-501.

Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83(2):265-72.

Rudra T, Webb DB, Evans AG. Acute tubular necrosis following co-trimoxazole therapy. Nephron. 1989;53(1):85-6.

Kaplan Mİ, Atakan H, Aydoğdu N, Aktoz T, Öz Puyan FG, et al. The effect of melatonin on cadmium-induced renal injury in chronically exposed rats. Turk J Urol. 2009;35(2):139-47.

Miller WG, Myers GL, Ashwood ER, Killeen AA, Wang E, Thienpont LM, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med. 2005;129(3):297-304.

Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother. 2012;67(5):1271-7.

Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med. 1999;246(3):247-52.

Botchet MV, Jacquiaud C, Valatin MA. Ritonavir and renal failure. N Engl J Med. 1997;336:138.

Duong M, Sgro C, Grappin M. Nelfinavir urinary stones. J Urol. 2002;167:1384-5.

Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119-25.

Adams A, De Kimpe N, Van Boekel MA. Modification of casein by the lipid oxidation product malondialdehyde. J Agric Food Chem. 2008;56(5):1713-9.

Ogbuehi I, Adikwu E, Oputiri D. Effect of Acalypha wilkesiana Muell Arg leaf extract on the oxidative indices, liver enzymes and liver integrity of rats infected with Plasmodium berghei. Br J Pharmacol Toxicol. 2014;5(2):68-74.

Zhang YM, Liu XZ, Lu H, Mei L, Liu ZP. Lipid peroxidation and ultrastructural modifications in brain after perinatal exposure to lead and/or cadmium in rat pups. Biomed Environ Sci. 2009;22(5):423-9.

Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol. 2007;224(1):60-71.

Wang D, Curtis A, Papp AC, Koletar SL, Para MF. Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. BMC Med Genomics. 2012;5:32.

Mozaffari A, Rashidi I. Investigation of protective effect of prednisolone in nephropathy induced by co-trimoxazole in rat. Pak J Med Sci (Part-II). 2007;23(6)847-50.

Cunha AM, Hagemanna CF, Simões RS, Oliveira-Filhob RM, Simões MJ, et al. Effects of lopinavir-ritonavir combined therapy during rat pregnancy. Morphological and biochemical aspects. Eur J Obstet Gynecol Reprod Biol. 2006;133(1):60-3.

Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999;56(3):570-80.

Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000;11(3):383-93.

Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002;54(1):37-45.

Elias A, Brambaifa N, Oputiri D, Oru-Bo OP. Antiretroviral toxicity and oxidative stress. Am J Pharmacol Toxicol. 2012;8(4):187-96.